DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wynalda, M. A.
Right arrow Articles by C. Wienkers, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wynalda, M. A.
Right arrow Articles by C. Wienkers, L.

0090-9556/97/2510-1211-1214$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 10


SHORT COMMUNICATION
Assessment of Potential Interactions Between Dopamine Receptor Agonists and Various Human Cytochrome P450 Enzymes Using a Simple In Vitro Inhibition Screen

Michael A. Wynalda and Larry C. Wienkers

Drug Metabolism Research Pharmacia & Upjohn

The selectivity of inhibition for four dopamine receptor agonists (pramipexole, ropinirole, pergolide, and bromocriptine) on six human cytochrome P450 enzyme activities were evaluated using a simple in vitro inhibition screen. Drug-P450 interactions characterized as potent (i.e. greater than 50% inhibition of control enzyme activity) were then further examined to determine an IC50 for the interaction. Of the dopamine receptor agonists tested, three drugs, ropinirole, pergolide, and bromocriptine, were found to inhibit the activity of at least one human cytochrome P450 enzyme, while the remaining dopamine agonist, pramipexole, was devoid of any potent P450 interaction. None of the agonists tested inhibited the P450 marker activities of 2C9, 2C19, and 2E1. However, partial inhibition was observed between ropinirole and CYP1A2 and pergolide and CYP3A4. In contrast, potent interactions were observed between CYP2D6 and pergolide and ropinirole, as well as with CYP3A4 and bromocriptine. The results of this study indicate several drug P450 interactions; however, the likelihood of an in vivo interaction with these drugs remains to be established.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. Nath, Y. V. Grinkova, S. G. Sligar, and W. M. Atkins
Ligand Binding to Cytochrome P450 3A4 in Phospholipid Bilayer Nanodiscs: THE EFFECT OF MODEL MEMBRANES
J. Biol. Chem., September 28, 2007; 282(39): 28309 - 28320.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Ekins, J. Berbaum, and R. K. Harrison
GENERATION AND VALIDATION OF RAPID COMPUTATIONAL FILTERS FOR CYP2D6 AND CYP3A4
Drug Metab. Dispos., September 1, 2003; 31(9): 1077 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. A. Wynalda, J. M. Hutzler, M. D. Koets, T. Podoll, and L. C. Wienkers
IN VITRO METABOLISM OF CLINDAMYCIN IN HUMAN LIVER AND INTESTINAL MICROSOMES
Drug Metab. Dispos., July 1, 2003; 31(7): 878 - 887.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. C. Wienkers and M. A. Wynalda
Multiple Cytochrome P450 Enzymes Responsible for the Oxidative Metabolism of the Substituted (S)-3-Phenylpiperidine, (S,S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine Hydrochloride, in Human Liver Microsomes
Drug Metab. Dispos., December 1, 2002; 30(12): 1372 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
F. Gao, D. L. Johnson, S. Ekins, J. Janiszewski, K. G. Kelly, R. D. Meyer, and M. West
Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50
J Biomol Screen, August 1, 2002; 7(4): 373 - 382.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. M. Stresser, A. P. Blanchard, S. D. Turner, J. C. L. Erve, A. A. Dandeneau, V. P. Miller, and C. L. Crespi
Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates
Drug Metab. Dispos., April 13, 2001; 28(12): 1440 - 1448.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. A. Wynalda, M. J. Hauer, and L. C. Wienkers
Oxidation of the Novel Oxazolidinone Antibiotic Linezolid in Human Liver Microsomes
Drug Metab. Dispos., September 1, 2000; 28(9): 1014 - 1017.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
L. C. Wienkers, C. Allievi, M. J. Hauer, and M. A. Wynalda
Cytochrome P-450-Mediated Metabolism of the Individual Enantiomers of the Antidepressant Agent Reboxetine in Human Liver Microsomes
Drug Metab. Dispos., November 1, 1999; 27(11): 1334 - 1340.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.